ANNE KINGORI: Open Payments
NPI 1376230128 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,615 in 90 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $664 · 2025 $2,615
Food & beverage: $2,615
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $667 |
| Axsome Therapeutics, Inc. | 11 | $452 |
| Neurocrine BioSciences, Inc. | 10 | $352 |
| ABBVIE INC. | 13 | $215 |
| Alkermes, Inc. | 5 | $184 |
| Otsuka America Pharmaceutical, Inc. | 11 | $168 |
| E.R. Squibb & Sons, L.L.C. | 3 | $138 |
| Teva Pharmaceuticals USA, Inc. | 4 | $137 |
| Corium, LLC | 6 | $90 |
| Noven Therapeutics, LLC | 2 | $43 |
Products named: CAPLYTA, Auvelity, INGREZZA, VRAYLAR, REXULTI, COBENFY, AUSTEDO XR, LYBALVI.
Industry payments across TX — which companies pay providers there.
